Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Video Roundtable: Industry Leaders Talk COVID-19, Strategy And The Year Ahead

Accord, mAbxience, PharmEvo And Sandoz Leaders Discuss Priorities For The Sector

Executive Summary

In this exclusive video roundtable discussion, leaders from across the off-patent industry talk about the COVID-19 pandemic and the industry’s response, as well as highlighting key regulatory, policy and strategic developments that may have flown under the radar in the past year.

You may also be interested in...



Accord Takes A Trio Of Awards

Accord Healthcare took home a trio of prizes at the Global Generics & Biosimilars Awards 2020, with other winners including Alvogen, Aurobindo, Dr Reddy’s, Eurofarma, Insud Pharma, Macleods, Pinsent Masons, Samsung Bioepis, Sandoz, Stada and Zentiva.

Bio-Thera Ventures Outside China With European Bevacizumab Filing

China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.

EU Pharma Strategy Will Remove Barriers And Bolster Competition

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel